Chestnut Hill, Mass. (Jan. 9, 2017) - Using ring-closing metathesis to exploit the properties of carbon-carbon double bonds, researchers from Boston College and the Massachusetts Institute of Technology have developed a new catalytic approach for the preparation of compounds essential to drug discovery, the team reported today in the journal Natures's advance online publication.
The catalyst, which contains the metal molybdenum, readily transforms a linear organic molecule that contains a C-C double bond substituted with a boronate group into an E isomer-selective macrocyclic compound through ring-closing metathesis, according to the researchers.
The new strategy was used to prepare the anti-cancer agent pacritinib, which is now in advanced clinical trials for the treatment of lymphoma and myelofibrosis, not only with high selectivity but also with 20 times less solvent than required by alternative methods, the team reported in the article "Kinetically E-selective macrocyclic ring-closing metathesis."
"As is often the case, the effective catalyst for a reaction must have many different characteristics. It should be robust yet sufficiently reactive; it should be able to give high selectivity and not subsequently destroy it. It is not easy to satisfy all of these requirements," said Boston College Vanderslice Millennium Professor of Chemistry Amir Hoveyda, a lead researcher on the team, along with MIT Keyes Professor of Chemistry and 2005 Nobel laureate Richard R. Schrock.
Research into innovative therapeutic drugs often focuses on "large ring" compounds that contain 12 or more atoms, comprised mainly of carbon. Many of the rings contain at least one carbon-carbon double bond, which are known as alkenes or olefins. The isomers of these bonds can be either Z-shaped or E-shaped. The challenge in fine chemical synthesis is separating the two in order to access the desired compound, Hoveyda said.
"It is typically impossible to separate these two isomers," said Hoveyda. "Yet, a drug's potency often depends on whether the double bond is E or Z. Even if separation of mixtures were possible, it is prohibitively expensive since half of the material would be discarded."
Hoveyda and Schrock, who have collaborated on research into catalysts for 20 years, set a precedent for their new approach five years ago, when their team prepared a Z-isomer carbon-carbon double bond in a large ring by means of ring-closing olefin metathesis.
"What led us to this approach was the result of years of trying to understand how this important class of transformations, called olefin metathesis, really works," said Hoveyda. "It was based on the knowledge gained from such investigations that we were eventually able to solve this problem."
Central to the advance, the team reported, is the stereoselective conversion of a linear hydrocarbon molecule that contains an E-alkenyl boron moiety into E-macrocyclic alkenes, with minimal formation of the undesired Z isomers.
"It is crucial that we have ways to access in a reliable manner samples of each isomer in high purity - 98 percent or more through this method," said Hoveyda. "Prior methods, as we show in the paper, give 15 to 50 percent -- at times even more -- of the undesired Z isomers that cannot be separated from the desired E isomers. Those samples are by and large useless as far as getting reliable results in biological testing is concerned."
In addition to Hoveyda and Schrock, co-authors of the report include Boston College post-doctoral researchers Xiao Shen and Alexander W.H. Speed, graduate students Thach T. Nguyen, and Ming Joo Koh, and BC undergraduate research assistant Dongmin Xu.
Researchers were surprised that high E selectivity was the result of the use of a boronate that is often used in an entirely different type of reactions, known as catalytic cross-coupling. The dramatic reduction in the use of a purifying solvent also cleared a major hurdle, particularly in the development of pacritinib, Hoveyda said.
Hoveyda said there are a number of unresolved challenges posed by the olefin metathesis class of chemical reactions. "We do not know if the catalysts and strategies that we already have developed will be good enough, or if we need to innovate," he said.